Kauppila A, Telimaa S, Rönnberg L, Vuori J
Department of Obstetrics and Gynecology, University of Oulu, Finland.
Fertil Steril. 1988 Jan;49(1):37-41. doi: 10.1016/s0015-0282(16)59644-7.
Serum concentrations of CA-125 were determined in association with 6-month medical (n = 48) or surgical and medical therapy (n = 40) of endometriosis. The concentration of CA-125 was significantly higher in stages III + IV (66.6 +/- 22.0 [standard deviation] U/ml) than in stage I (20.9 +/- 2.3 U/ml) or II (28.4 +/- 2.8 U/ml); in stage II, the concentration was higher than in stage I. Surgical elimination of endometriosis significantly decreased the level of CA-125, as did danazol, but not medroxyprogesterone acetate (MPA), although these drugs were equal in clinical efficacy. The CA-125 changes during hormonal treatment did not correlate with the clinical response. Postoperatively, CA-125 responses to danazol, MPA, or placebo did not differ significantly from each other. During the 6-month follow-up after medication, the CA-125 concentrations tended to increase, especially in danazol-treated women. The determination of CA-125 is useful in estimating the extent of the disease, but it is less valuable in monitoring the treatment effect. The ability of danazol to suppress CA-125 expression emphasizes the specific properties of this drug.
测定了子宫内膜异位症患者血清CA - 125浓度，这些患者接受了为期6个月的药物治疗（n = 48）或手术联合药物治疗（n = 40）。III + IV期患者的CA - 125浓度（66.6 +/- 22.0[标准差]U/ml）显著高于I期（20.9 +/- 2.3 U/ml）或II期（28.4 +/- 2.8 U/ml）；II期患者的浓度高于I期。手术切除子宫内膜异位症可显著降低CA - 125水平，达那唑也有同样效果，但醋酸甲羟孕酮（MPA）则不然，尽管这些药物的临床疗效相当。激素治疗期间CA - 125的变化与临床反应无关。术后，CA - 125对达那唑、MPA或安慰剂的反应彼此间无显著差异。在用药后的6个月随访期间，CA - 125浓度有升高趋势，尤其是在接受达那唑治疗的女性中。CA - 125的测定有助于评估疾病的程度，但在监测治疗效果方面价值较小。达那唑抑制CA - 125表达的能力凸显了该药的特殊性质。
